Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-24-023906
Filing Date
2024-09-24
Accepted
2024-09-24 17:00:07
Documents
1
Period of Report
2024-09-23

Document Format Files

Seq Description Document Type Size
1 form4-09242024_050902.html 4  
1 form4-09242024_050902.xml 4 4838
  Complete submission text file 0001415889-24-023906.txt   6499
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 2 SNUNIT STREET SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address
Naos Yaron (Reporting) CIK: 0001742727 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 241320744